Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Malignant Mesothelioma: Time to Translate?

Napolitano A, Carbone M.

Trends Cancer. 2016 Sep;2(9):467-474. doi: 10.1016/j.trecan.2016.07.004.

2.

Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer.

Ata R, Antonescu CN.

Int J Mol Sci. 2017 Jan 18;18(1). pii: E189. doi: 10.3390/ijms18010189. Review.

3.

Integrins in the Spotlight of Cancer.

Bianconi D, Unseld M, Prager GW.

Int J Mol Sci. 2016 Dec 6;17(12). pii: E2037. Review.

4.

Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.

Chen YB, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, Won HH, Wang PI, Nanjangud GJ, Jungbluth AA, Li W, Ojeda V, Hakimi AA, Voss MH, Schultz N, Motzer RJ, Russo P, Cheng EH, Giancotti FG, Lee W, Berger MF, Tickoo SK, Reuter VE, Hsieh JJ.

Nat Commun. 2016 Oct 7;7:13131. doi: 10.1038/ncomms13131.

5.

Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease.

Chernova T, Sun XM, Powley IR, Galavotti S, Grosso S, Murphy FA, Miles GJ, Cresswell L, Antonov AV, Bennett J, Nakas A, Dinsdale D, Cain K, Bushell M, Willis AE, MacFarlane M.

Cell Death Differ. 2016 Jul;23(7):1152-64. doi: 10.1038/cdd.2015.165. Epub 2016 Feb 19.

6.

The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications.

Sang Y, Yan F, Ren X.

Oncotarget. 2015 Dec 15;6(40):42590-602. doi: 10.18632/oncotarget.6052. Review.

7.

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R, Fagin JA.

Cancer Discov. 2015 Nov;5(11):1178-93. doi: 10.1158/2159-8290.CD-15-0330. Epub 2015 Sep 10.

8.

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Bononi A, Napolitano A, Pass HI, Yang H, Carbone M.

Expert Rev Respir Med. 2015 Oct;9(5):633-54. doi: 10.1586/17476348.2015.1081066. Epub 2015 Aug 26. Review.

9.

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.

Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao WN, Jordan JT, Stemmer-Rachamimov A, Plotkin SR, Gusella JF, Haggarty SJ, Ramesh V.

Oncotarget. 2015 Jul 10;6(19):16981-97.

10.

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.

Echeverry N, Ziltener G, Barbone D, Weder W, Stahel RA, Broaddus VC, Felley-Bosco E.

Cell Death Dis. 2015 May 7;6:e1757. doi: 10.1038/cddis.2015.124.

11.

Role of Merlin/NF2 inactivation in tumor biology.

Petrilli AM, Fernández-Valle C.

Oncogene. 2016 Feb 4;35(5):537-48. doi: 10.1038/onc.2015.125. Epub 2015 Apr 20. Review.

12.

SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR.

J Thorac Oncol. 2015 Feb;10(2):387-91. doi: 10.1097/JTO.0000000000000360.

13.

Neurofibromatosis-related tumors: emerging biology and therapies.

Karajannis MA, Ferner RE.

Curr Opin Pediatr. 2015 Feb;27(1):26-33. doi: 10.1097/MOP.0000000000000169. Review.

14.

Current issues in malignant pleural mesothelioma evaluation and management.

Ai J, Stevenson JP.

Oncologist. 2014 Sep;19(9):975-84. doi: 10.1634/theoncologist.2014-0122. Epub 2014 Jul 24.

15.

Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Malaguarnera R, Chen KY, Kim TY, Dominguez JM, Voza F, Ouyang B, Vundavalli SK, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1976-87. doi: 10.1210/jc.2013-3976. Epub 2014 Jul 16.

16.

p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Ahmad I, Yue WY, Fernando A, Clark JJ, Woodson EA, Hansen MR.

Glia. 2014 Oct;62(10):1699-712. doi: 10.1002/glia.22709. Epub 2014 Jun 26.

17.

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K.

Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9.

18.

Molecular insights into NF2/Merlin tumor suppressor function.

Cooper J, Giancotti FG.

FEBS Lett. 2014 Aug 19;588(16):2743-52. doi: 10.1016/j.febslet.2014.04.001. Epub 2014 Apr 12. Review.

19.

A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma.

Nishikawa S, Tanaka A, Matsuda A, Oida K, Jang H, Jung K, Amagai Y, Ahn G, Okamoto N, Ishizaka S, Matsuda H.

Cancer Med. 2014 Apr;3(2):416-25. doi: 10.1002/cam4.202. Epub 2014 Feb 10.

20.

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M.

Neuro Oncol. 2014 Apr;16(4):493-504. doi: 10.1093/neuonc/not242. Epub 2014 Jan 10.

Supplemental Content

Support Center